IntraBio Inc. has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking approval of levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T), a rare and progressive neurodegenerative disorder affecting approximately one in 70,000 people. The Austin-based biopharmaceutical company is building on the existing U.S. approval of levacetylleucine for Niemann-Pick disease type C, using the sNDA route to expand its label rather than filing a new NDA from scratch. This submission marks the first regulatory application ever filed with the FDA seeking approval of a treatment specifically for A-T.

The use of the supplemental pathway is analytically significant. IntraBio already holds NPC approval, meaning levacetylleucine has cleared the FDA’s full safety review once. The sNDA mechanism allows the agency to evaluate new efficacy evidence against a drug with an established safety record, which typically reduces the risk of safety-based rejection and can streamline the review timeline. For a company operating in ultra-rare disease territory, where commercial scale is limited and reimbursement negotiations are complex, minimising regulatory friction matters considerably. The strategy reflects a deliberate platform-building approach: demonstrate efficacy sequentially across related neurological indications, each filing reinforcing the asset’s credibility.

What the crossover trial design reveals about the evidence package IntraBio is presenting

The pivotal Phase III trial (IB1001-303) was conducted as a randomised, double-blind, placebo-controlled crossover study in adult and paediatric patients with A-T. The crossover design is worth examining carefully because it carries specific methodological advantages and limitations in rare disease settings. By using each patient as their own control, the design removes inter-subject variability, which is especially useful when working with small, heterogeneous populations where randomisation alone cannot fully balance baseline differences. This approach likely allowed IntraBio to demonstrate statistically significant effects with a smaller patient cohort than a parallel-arm trial would have required, which is a pragmatic necessity in a condition affecting an estimated one in 70,000 live births.

The primary endpoint was improvement on the Scale for the Assessment and Rating of Ataxia (SARA), a validated neurological tool measuring coordination, gait, speech, and fine motor function. Levacetylleucine produced a statistically significant improvement of 1.88 points compared to placebo after 12 weeks of treatment. Secondary endpoints included the International Cooperative Ataxia Rating Scale (ICARS), where the drug generated a 4.22-point improvement against a 1.69-point improvement on placebo (p=0.003), and the Investigator’s Clinical Global Impression of Improvement (CGI-I), which showed a 0.6-point improvement versus 0.2 on placebo (p=0.02). The consistency across multiple validated ataxia instruments strengthens the evidence package and reduces the risk of the FDA questioning whether any single endpoint captured a clinically meaningful effect.

Crossover designs in progressive neurodegenerative disease do introduce interpretive complexity, however. A-T is characterised by continuous cerebellar degeneration, and any carryover effects between treatment periods must be carefully accounted for in the statistical analysis. The 12-week treatment window raises the question of whether improvements observed in the first period persisted, plateaued, or deteriorated once patients crossed to placebo. IntraBio has not yet published the full dataset in a peer-reviewed journal, meaning independent clinical assessment of the raw data is not yet possible. Regulators and clinicians tracking the field will likely focus on whether the magnitude of SARA improvement translates to measurable real-world functional gains for patients at different stages of disease progression.

How levacetylleucine’s mechanism of action applies across different neurological conditions

Levacetylleucine is the L-enantiomer of N-acetyl-leucine, a modified form of the amino acid leucine that crosses the blood-brain barrier via monocarboxylate transporters. Its proposed mechanism centres on stabilising lysosomal function and restoring intracellular lipid trafficking, processes disrupted in both NPC and A-T through different genetic pathways. In NPC, the primary defect is in NPC1 or NPC2 protein function, causing cholesterol and sphingolipid accumulation. In A-T, the underlying cause is loss-of-function mutation in the ATM gene, which encodes a kinase critical for DNA damage response. The lysosomal and mitochondrial stress pathways downstream of ATM loss create a different but partially overlapping cellular environment to NPC, which is the mechanistic rationale for exploring the same compound across both indications.

This cross-indication strategy is genuinely novel rather than merely opportunistic. If levacetylleucine’s benefit in A-T reflects a disease-agnostic effect on shared downstream neurological stress pathways rather than correction of the primary genetic defect, it opens a plausible development thesis for other cerebellar ataxias and lysosomal storage disorders. IntraBio has already flagged CACNA1A-related disorders and additional ataxias as pipeline targets, and the company has a separate GM2 Gangliosidosis programme (covering Tay-Sachs and Sandhoff disease) using the same compound. Each positive regulatory submission compounds the asset’s credibility, even as the precise mechanistic picture across indications remains incompletely characterised.

What the absence of any prior approved therapy means for adoption and pricing dynamics

A-T has no currently approved therapy anywhere in the world. The condition typically presents in early childhood and follows a relentless degenerative course: most patients require wheelchair assistance by their teens, and median life expectancy has historically been in the late twenties to early thirties, with respiratory failure and cancer accounting for the majority of deaths. The complete absence of approved pharmacotherapy means that if the FDA approves the sNDA, IntraBio enters the market without any direct branded competition, a rare regulatory and commercial position. Orphan drug designation, which the company holds for A-T, provides seven years of market exclusivity following approval in the United States, along with priority review voucher eligibility that carries substantial transferable value independent of the drug’s commercial performance.

The reimbursement environment, however, presents structural challenges that first-in-disease status does not automatically resolve. Payers assessing an A-T therapy will confront several difficulties: the small and geographically dispersed patient population limits head-to-head cost-effectiveness modelling against existing treatments, because none exist; the multi-system nature of A-T (neurological, immunological, oncological) makes outcome attribution across care pathways difficult to standardise; and the absence of long-term data beyond 12 weeks in the pivotal study will likely prompt payers to seek post-approval evidence before committing to unrestricted reimbursement. Real-world evidence generation and registry-based follow-up will therefore be critical commercial enablers, not merely regulatory formalities.

What the FDA review timeline and EMA parallel submission suggest about IntraBio’s regulatory posture

IntraBio has confirmed it is pursuing parallel regulatory submissions to the FDA, the European Medicines Agency, and additional global authorities. The FDA’s standard review clock for sNDAs under priority review is six months from acceptance; standard review runs twelve months. Given the orphan designation and the absence of approved alternatives, priority review designation is probable, placing a potential approval decision within the second half of 2026 if the agency accepts the filing promptly. In Europe, the EMA’s Committee for Medicinal Products for Human Use evaluates label expansion applications through a similar but procedurally distinct process, and IntraBio’s existing EU authorisation for levacetylleucine in NPC may accelerate familiarity with the compound’s safety dossier.

Regulatory watchers suggest the primary review risk centres on whether the FDA will accept the 12-week duration of the crossover trial as sufficient to demonstrate a durable and clinically meaningful effect in a condition characterised by lifelong progression. The agency may request longer-term open-label extension data, a risk that would push the approval timeline out but would not necessarily be fatal to the programme. A complete response letter requesting additional data is a scenario the market should not discount entirely, given the design features of the crossover study and the complexity of demonstrating sustained benefit in paediatric populations.

What clinicians and industry observers will watch as the FDA review proceeds in 2026

For neurologists managing A-T patients, the most pressing clinical question is whether the degree of SARA improvement observed in the trial translates into functionally meaningful outcomes for patients across the spectrum of disease severity. SARA is a validated and widely used research instrument, but its relationship to activities of daily living, quality of life, and caregiver burden in A-T specifically is less well established than in some other cerebellar ataxias. Clinicians will also note that A-T carries significant immune and oncological comorbidities that levacetylleucine is not designed to address, meaning any approved therapy treats the neurological dimension of the disease while leaving the broader disease burden substantially unmodified.

For the broader rare neurological disease field, IntraBio’s programme carries strategic relevance beyond A-T itself. The company’s approach of identifying a single modified amino acid with broad lysosomal and neurological activity, validating it sequentially across multiple rare conditions with high unmet need, and building a portfolio of orphan indications from one chemical entity represents a capital-efficient model that other small-molecule rare disease developers will examine closely. The outcome of this sNDA will test whether that model holds up to the FDA’s evidentiary standards when applied outside the original indication, and whether a crossover trial of twelve weeks is structurally sufficient to carry a label expansion in a severe paediatric neurodegenerative disease.

  AQNEURSA, Ataxia-Telangiectasia, ATM gene, cerebellar ataxia, FDA, IntraBio, levacetylleucine, lysosomal storage disorder, neurodegenerative disease, Niemann-Pick disease, orphan drug, paediatric neurology, phase III, rare disease, SARA, sNDA